CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions.
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of immunotherapy for the treatment of hematologic malignancies. The two primary toxicities associated with CAR T-cell therapy include cytokine release syndrome (CRS) and neurotoxicity (NT). CRS is generally self-limited but high-grade toxicities like hypotension and hypoxemia can be managed with agents that block the effects of IL-6, like tocilizumab, and/or corticosteroids. While CAR-T cell therapy-associated NT is a well-described clinical phenomenon, its pathophysiology remains inadequately understood; treatments and preventive strategies remain elusive. Animal models and clinical trial experience suggest the centrality of monocytes, endothelial dysfunction, and the blood brain barrier in the development of CAR T-cell associated NT. Here we report what is known from pre-clinical models, clinical trials, and histopathologic studies regarding the pathophysiology of NT, predictors of its incidence, and potential targets for the treatment and prevention of NT.